A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy
|Johnson & Johnson
|Male and Female Patients
|U.S. Govt. ID:
|Ryan Shelton: 212-304-5485 / firstname.lastname@example.org
The purpose of this study is to find out how well Daratumumab works when it is given along with two other drugs called Lenalidomide and Dexamethasone compared to the drug combination of Lenalidomide and Dexamethasone to treat multiple myeloma.
This study is closed
Divaya Bhutani, MD
|Do you have multiple myeloma?